| Drug Name |
Vandetanib |
| Drug ID |
BADD_D02334 |
| Description |
Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types.
On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. |
| Indications and Usage |
Vandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease. Because Vandetanib can prolong the Q-T interval, it is contraindicated for use in patients with serious cardiac complications such as congenital long QT syndrome and uncompensated heart failure. |
| Marketing Status |
approved |
| ATC Code |
L01EX04 |
| DrugBank ID |
DB05294
|
| KEGG ID |
D06407
|
| MeSH ID |
C452423
|
| PubChem ID |
3081361
|
| TTD Drug ID |
D0G6QF
|
| NDC Product Code |
58468-7840; 69988-0054; 49187-0220; 58468-7820; 58468-7860 |
| UNII |
YO460OQ37K
|
| Synonyms |
vandetanib | N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine | ZD 6474 | ZD6474 | ZD-6474 | ZD-64 | Caprelsa | Zactima |
